Serveur d'exploration sur les relations entre la France et l'Australie

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen

Identifieur interne : 008997 ( Main/Exploration ); précédent : 008996; suivant : 008998

Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen

Auteurs : Susan R. Davis [Australie] ; Michele Moreau [Canada] ; Robin Kroll [États-Unis] ; Céline Bouchard [Canada] ; Nick Panay [Royaume-Uni] ; Margery Gass [États-Unis] ; Glenn D. Braunstein [États-Unis] ; Angelica Linden Hirschberg [Suède] ; Cynthia Rodenberg [États-Unis] ; Simon Pack [États-Unis] ; Helga Koch [États-Unis] ; Alain Moufarege [France] ; John Studd [Royaume-Uni]

Source :

RBID : Pascal:08-0528793

Descripteurs français

English descriptors

Abstract

BACKGROUND The efficacy and safety of testosterone treatment for hypoactive sexual desire disorder in postmenopausal women not receiving estrogen therapy are unknown. METHODS We conducted a double-blind, placebo-controlled, 52-week trial in which 814 women with hypoactive sexual desire disorder were randomly assigned to receive a patch delivering 150 or 300 μg of testosterone per day or placebo. Efficacy was measured to week 24; safety was evaluated over a period of 52 weeks, with a subgroup of participants followed for an additional year. The primary end point was the change from baseline to week 24 in the 4-week frequency of satisfying sexual episodes. RESULTS At 24 weeks, the increase in the 4-week frequency of satisfying sexual episodes was significantly greater in the group receiving 300 μg of testosterone per day than in the placebo group (an increase of 2.1 episodes vs. 0.7, P<0.001) but not in the group receiving 150 μg per day (1.2 episodes, P=0.11). As compared with placebo, both doses of testosterone were associated with significant increases in desire (300 μg per day, P<0.001; 150 μg per day, P=0.04) and decreases in distress (300 μg per day, P<0.001; 150 μg per day, P=0.04). The rate of androgenic adverse events - primarily unwanted hair growth - was higher in the group receiving 300 μg of testosterone per day than in the placebo group (30.0% vs. 23.1%). Breast cancer was diagnosed in four women who received testosterone (as compared with none who received placebo); one of the four received the diagnosis in the first 4 months of the study period, and one, in retrospect, had symptoms before undergoing randomization. CONCLUSIONS In postmenopausal women not receiving estrogen therapy, treatment with a patch delivering 300 μg of testosterone per day resulted in a modest but meaningful improvement in sexual function. The long-term effects of testosterone, including effects on the breast, remain uncertain. (ClinicalTrials.gov number, NCT00131495.)


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen</title>
<author>
<name sortKey="Davis, Susan R" sort="Davis, Susan R" uniqKey="Davis S" first="Susan R." last="Davis">Susan R. Davis</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Women's Health Program, Monash University, Alfred Hospital</s1>
<s2>Prahran</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Prahran</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Moreau, Michele" sort="Moreau, Michele" uniqKey="Moreau M" first="Michele" last="Moreau">Michele Moreau</name>
<affiliation wicri:level="3">
<inist:fA14 i1="02">
<s1>Centre d'Etude Clinique</s1>
<s2>Montreal</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kroll, Robin" sort="Kroll, Robin" uniqKey="Kroll R" first="Robin" last="Kroll">Robin Kroll</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Women's Clinical Research Center and the Menopause Center of Seattle</s1>
<s2>Seattle</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Women's Clinical Research Center and the Menopause Center of Seattle</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Bouchard, Celine" sort="Bouchard, Celine" uniqKey="Bouchard C" first="Céline" last="Bouchard">Céline Bouchard</name>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Université Laval</s1>
<s2>Quebec, QC</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Université Laval</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Panay, Nick" sort="Panay, Nick" uniqKey="Panay N" first="Nick" last="Panay">Nick Panay</name>
<affiliation wicri:level="3">
<inist:fA14 i1="05">
<s1>Queen Charlotte's and Chelsea Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gass, Margery" sort="Gass, Margery" uniqKey="Gass M" first="Margery" last="Gass">Margery Gass</name>
<affiliation wicri:level="1">
<inist:fA14 i1="06">
<s1>University of Cincinnati College of Medicine</s1>
<s2>Cincinnati</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Cincinnati College of Medicine</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Braunstein, Glenn D" sort="Braunstein, Glenn D" uniqKey="Braunstein G" first="Glenn D." last="Braunstein">Glenn D. Braunstein</name>
<affiliation wicri:level="3">
<inist:fA14 i1="07">
<s1>Cedars-Sinai Medical Center</s1>
<s2>Los Angeles</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<settlement type="city">Los Angeles</settlement>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Linden Hirschberg, Angelica" sort="Linden Hirschberg, Angelica" uniqKey="Linden Hirschberg A" first="Angelica" last="Linden Hirschberg">Angelica Linden Hirschberg</name>
<affiliation wicri:level="3">
<inist:fA14 i1="08">
<s1>Karolinska University Hospital</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName>
<settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Rodenberg, Cynthia" sort="Rodenberg, Cynthia" uniqKey="Rodenberg C" first="Cynthia" last="Rodenberg">Cynthia Rodenberg</name>
<affiliation wicri:level="1">
<inist:fA14 i1="09">
<s1>Procter & Gamble Pharmaceuticals</s1>
<s2>Mason, OH</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Procter & Gamble Pharmaceuticals</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Pack, Simon" sort="Pack, Simon" uniqKey="Pack S" first="Simon" last="Pack">Simon Pack</name>
<affiliation wicri:level="1">
<inist:fA14 i1="09">
<s1>Procter & Gamble Pharmaceuticals</s1>
<s2>Mason, OH</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Procter & Gamble Pharmaceuticals</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Koch, Helga" sort="Koch, Helga" uniqKey="Koch H" first="Helga" last="Koch">Helga Koch</name>
<affiliation wicri:level="1">
<inist:fA14 i1="09">
<s1>Procter & Gamble Pharmaceuticals</s1>
<s2>Mason, OH</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Procter & Gamble Pharmaceuticals</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Moufarege, Alain" sort="Moufarege, Alain" uniqKey="Moufarege A" first="Alain" last="Moufarege">Alain Moufarege</name>
<affiliation wicri:level="1">
<inist:fA14 i1="10">
<s1>Debiopharm Group</s1>
<s2>Charenton-le-Pont</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Charenton-le-Pont</wicri:noRegion>
<wicri:noRegion>Debiopharm Group</wicri:noRegion>
<wicri:noRegion>Debiopharm Group</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Studd, John" sort="Studd, John" uniqKey="Studd J" first="John" last="Studd">John Studd</name>
<affiliation wicri:level="3">
<inist:fA14 i1="11">
<s1>Chelsea and Westminster Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">08-0528793</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0528793 INIST</idno>
<idno type="RBID">Pascal:08-0528793</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003185</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002E68</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002E59</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002E59</idno>
<idno type="wicri:doubleKey">0028-4793:2008:Davis S:testosterone:for:low</idno>
<idno type="wicri:Area/Main/Merge">009273</idno>
<idno type="wicri:Area/Main/Curation">008997</idno>
<idno type="wicri:Area/Main/Exploration">008997</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen</title>
<author>
<name sortKey="Davis, Susan R" sort="Davis, Susan R" uniqKey="Davis S" first="Susan R." last="Davis">Susan R. Davis</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Women's Health Program, Monash University, Alfred Hospital</s1>
<s2>Prahran</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Prahran</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Moreau, Michele" sort="Moreau, Michele" uniqKey="Moreau M" first="Michele" last="Moreau">Michele Moreau</name>
<affiliation wicri:level="3">
<inist:fA14 i1="02">
<s1>Centre d'Etude Clinique</s1>
<s2>Montreal</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kroll, Robin" sort="Kroll, Robin" uniqKey="Kroll R" first="Robin" last="Kroll">Robin Kroll</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Women's Clinical Research Center and the Menopause Center of Seattle</s1>
<s2>Seattle</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Women's Clinical Research Center and the Menopause Center of Seattle</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Bouchard, Celine" sort="Bouchard, Celine" uniqKey="Bouchard C" first="Céline" last="Bouchard">Céline Bouchard</name>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Université Laval</s1>
<s2>Quebec, QC</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Université Laval</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Panay, Nick" sort="Panay, Nick" uniqKey="Panay N" first="Nick" last="Panay">Nick Panay</name>
<affiliation wicri:level="3">
<inist:fA14 i1="05">
<s1>Queen Charlotte's and Chelsea Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gass, Margery" sort="Gass, Margery" uniqKey="Gass M" first="Margery" last="Gass">Margery Gass</name>
<affiliation wicri:level="1">
<inist:fA14 i1="06">
<s1>University of Cincinnati College of Medicine</s1>
<s2>Cincinnati</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Cincinnati College of Medicine</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Braunstein, Glenn D" sort="Braunstein, Glenn D" uniqKey="Braunstein G" first="Glenn D." last="Braunstein">Glenn D. Braunstein</name>
<affiliation wicri:level="3">
<inist:fA14 i1="07">
<s1>Cedars-Sinai Medical Center</s1>
<s2>Los Angeles</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<settlement type="city">Los Angeles</settlement>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Linden Hirschberg, Angelica" sort="Linden Hirschberg, Angelica" uniqKey="Linden Hirschberg A" first="Angelica" last="Linden Hirschberg">Angelica Linden Hirschberg</name>
<affiliation wicri:level="3">
<inist:fA14 i1="08">
<s1>Karolinska University Hospital</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName>
<settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Rodenberg, Cynthia" sort="Rodenberg, Cynthia" uniqKey="Rodenberg C" first="Cynthia" last="Rodenberg">Cynthia Rodenberg</name>
<affiliation wicri:level="1">
<inist:fA14 i1="09">
<s1>Procter & Gamble Pharmaceuticals</s1>
<s2>Mason, OH</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Procter & Gamble Pharmaceuticals</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Pack, Simon" sort="Pack, Simon" uniqKey="Pack S" first="Simon" last="Pack">Simon Pack</name>
<affiliation wicri:level="1">
<inist:fA14 i1="09">
<s1>Procter & Gamble Pharmaceuticals</s1>
<s2>Mason, OH</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Procter & Gamble Pharmaceuticals</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Koch, Helga" sort="Koch, Helga" uniqKey="Koch H" first="Helga" last="Koch">Helga Koch</name>
<affiliation wicri:level="1">
<inist:fA14 i1="09">
<s1>Procter & Gamble Pharmaceuticals</s1>
<s2>Mason, OH</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Procter & Gamble Pharmaceuticals</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Moufarege, Alain" sort="Moufarege, Alain" uniqKey="Moufarege A" first="Alain" last="Moufarege">Alain Moufarege</name>
<affiliation wicri:level="1">
<inist:fA14 i1="10">
<s1>Debiopharm Group</s1>
<s2>Charenton-le-Pont</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Charenton-le-Pont</wicri:noRegion>
<wicri:noRegion>Debiopharm Group</wicri:noRegion>
<wicri:noRegion>Debiopharm Group</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Studd, John" sort="Studd, John" uniqKey="Studd J" first="John" last="Studd">John Studd</name>
<affiliation wicri:level="3">
<inist:fA14 i1="11">
<s1>Chelsea and Westminster Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">The New England journal of medicine</title>
<title level="j" type="abbreviated">N. Engl. j. med.</title>
<idno type="ISSN">0028-4793</idno>
<imprint>
<date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">The New England journal of medicine</title>
<title level="j" type="abbreviated">N. Engl. j. med.</title>
<idno type="ISSN">0028-4793</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Estrogen</term>
<term>Female</term>
<term>Libido</term>
<term>Medicine</term>
<term>Postmenopause</term>
<term>Sex steroid hormone</term>
<term>Testosterone</term>
<term>Woman</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Testostérone</term>
<term>Hormone stéroïde sexuelle</term>
<term>Libido</term>
<term>Postménopause</term>
<term>Femelle</term>
<term>Femme</term>
<term>Adulte</term>
<term>Oestrogène</term>
<term>Médecine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Femme</term>
<term>Adulte</term>
<term>Médecine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">BACKGROUND The efficacy and safety of testosterone treatment for hypoactive sexual desire disorder in postmenopausal women not receiving estrogen therapy are unknown. METHODS We conducted a double-blind, placebo-controlled, 52-week trial in which 814 women with hypoactive sexual desire disorder were randomly assigned to receive a patch delivering 150 or 300 μg of testosterone per day or placebo. Efficacy was measured to week 24; safety was evaluated over a period of 52 weeks, with a subgroup of participants followed for an additional year. The primary end point was the change from baseline to week 24 in the 4-week frequency of satisfying sexual episodes. RESULTS At 24 weeks, the increase in the 4-week frequency of satisfying sexual episodes was significantly greater in the group receiving 300 μg of testosterone per day than in the placebo group (an increase of 2.1 episodes vs. 0.7, P<0.001) but not in the group receiving 150 μg per day (1.2 episodes, P=0.11). As compared with placebo, both doses of testosterone were associated with significant increases in desire (300 μg per day, P<0.001; 150 μg per day, P=0.04) and decreases in distress (300 μg per day, P<0.001; 150 μg per day, P=0.04). The rate of androgenic adverse events - primarily unwanted hair growth - was higher in the group receiving 300 μg of testosterone per day than in the placebo group (30.0% vs. 23.1%). Breast cancer was diagnosed in four women who received testosterone (as compared with none who received placebo); one of the four received the diagnosis in the first 4 months of the study period, and one, in retrospect, had symptoms before undergoing randomization. CONCLUSIONS In postmenopausal women not receiving estrogen therapy, treatment with a patch delivering 300 μg of testosterone per day resulted in a modest but meaningful improvement in sexual function. The long-term effects of testosterone, including effects on the breast, remain uncertain. (ClinicalTrials.gov number, NCT00131495.)</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Australie</li>
<li>Canada</li>
<li>France</li>
<li>Royaume-Uni</li>
<li>Suède</li>
<li>États-Unis</li>
</country>
<region>
<li>Angleterre</li>
<li>Californie</li>
<li>Grand Londres</li>
<li>Québec</li>
<li>Svealand</li>
</region>
<settlement>
<li>Londres</li>
<li>Los Angeles</li>
<li>Montréal</li>
<li>Stockholm</li>
</settlement>
</list>
<tree>
<country name="Australie">
<noRegion>
<name sortKey="Davis, Susan R" sort="Davis, Susan R" uniqKey="Davis S" first="Susan R." last="Davis">Susan R. Davis</name>
</noRegion>
</country>
<country name="Canada">
<region name="Québec">
<name sortKey="Moreau, Michele" sort="Moreau, Michele" uniqKey="Moreau M" first="Michele" last="Moreau">Michele Moreau</name>
</region>
<name sortKey="Bouchard, Celine" sort="Bouchard, Celine" uniqKey="Bouchard C" first="Céline" last="Bouchard">Céline Bouchard</name>
</country>
<country name="États-Unis">
<noRegion>
<name sortKey="Kroll, Robin" sort="Kroll, Robin" uniqKey="Kroll R" first="Robin" last="Kroll">Robin Kroll</name>
</noRegion>
<name sortKey="Braunstein, Glenn D" sort="Braunstein, Glenn D" uniqKey="Braunstein G" first="Glenn D." last="Braunstein">Glenn D. Braunstein</name>
<name sortKey="Gass, Margery" sort="Gass, Margery" uniqKey="Gass M" first="Margery" last="Gass">Margery Gass</name>
<name sortKey="Koch, Helga" sort="Koch, Helga" uniqKey="Koch H" first="Helga" last="Koch">Helga Koch</name>
<name sortKey="Pack, Simon" sort="Pack, Simon" uniqKey="Pack S" first="Simon" last="Pack">Simon Pack</name>
<name sortKey="Rodenberg, Cynthia" sort="Rodenberg, Cynthia" uniqKey="Rodenberg C" first="Cynthia" last="Rodenberg">Cynthia Rodenberg</name>
</country>
<country name="Royaume-Uni">
<region name="Angleterre">
<name sortKey="Panay, Nick" sort="Panay, Nick" uniqKey="Panay N" first="Nick" last="Panay">Nick Panay</name>
</region>
<name sortKey="Studd, John" sort="Studd, John" uniqKey="Studd J" first="John" last="Studd">John Studd</name>
</country>
<country name="Suède">
<region name="Svealand">
<name sortKey="Linden Hirschberg, Angelica" sort="Linden Hirschberg, Angelica" uniqKey="Linden Hirschberg A" first="Angelica" last="Linden Hirschberg">Angelica Linden Hirschberg</name>
</region>
</country>
<country name="France">
<noRegion>
<name sortKey="Moufarege, Alain" sort="Moufarege, Alain" uniqKey="Moufarege A" first="Alain" last="Moufarege">Alain Moufarege</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008997 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008997 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:08-0528793
   |texte=   Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024